Immunotherapy in @entity1 with allergic asthma: effect on XXXX and pharmacotherapy.

@entity1 @entity2023 @entity565 @entity566 @entity4184 @entity112 @entity6587 @entity288
BACKGROUND: Immunotherapy has been shown to reduce allergen sensitivity to allergens such as cat and dust mite. The aim of this study was to investigate the effect of cat or dust mite immunotherapy on @entity6587 and the need for inhaled @entity288 in @entity1 with @entity565 , cat or dust mite @entity566 , and @entity2023 . SUBJECTS: Twenty-nine @entity1 , 7 to 16 years old, completed the 3-year study. They were randomly allocated to receive cat/dust mite or placebo and birch/timothy immunotherapy. METHODS: Before immunotherapy was begun and then once each year, bronchial @entity112 challenges were performed. Bronchial allergen challenge with the perennial allergen was done before and after the 3-year study. Pharmacotherapy was given according to a standardized protocol. RESULTS: PC20 allergen increased significantly in both the active immunotherapy group (P <.001) and in the placebo-pollen group (P <.05). PC20 @entity112 increased continuously in the active immunotherapy group (P <.05 and P =.002 after 1 and 3 years, respectively) and had also increased after 3 years in the placebo-pollen group (P <.05). The difference between the 2 groups was significant for PC20 allergen (P =.001) but not for PC20 @entity112 . There was no significant change in the dose of inhaled @entity4184 needed for symptom control in either of the groups. CONCLUSION: Pollen immunotherapy combined with inhaled corticosteroids results in improvement of both cat/dust mite bronchial sensitivity and hyperresponsiveness to @entity112 . The combination of cat or dust mite, pollen immunotherapy, and inhaled @entity4184 enhances this improvement. Cat immunotherapy also induces cat allergen tolerance.
